A Novel Polymer-Conjugated Human IL-15 Improves Efficacy of CD19-Targeted CAR-T Cell Immunotherapy

In vivo studies in lymphoma-bearing immunodeficient mice demonstrated enhanced antitumor efficacy of human CD19 CAR-T. In contrast to mice treated with CAR-T alone, those that received CAR-T and NKTR-255 had markedly higher CAR-T counts in blood and marrow.